Alergosan solution 0.5mg/ml 120 ml

Allergosan® oral solution is prescribed to adults and children over 12 years of age to relieve symptoms associated with:

Composition

Active ingredient: desloratadine.

1 ml of oral solution contains 0.5 mg of desloratadine.

Excipients: propylene glycol; sodium citrate; citric acid, monohydrate; disodium edetate; sorbitol solution, non-crystallizing (E 420); sucralose; hypromellose; cherry flavoring; purified water.

Contraindication

Hypersensitivity to the active substance or to any of the excipients of the drug or to loratadine.

Method of application

Administer orally, regardless of food intake.

Adults and children over 12 years of age: 10 ml of solution (5 mg of desloratadine) once a day.

Treatment of intermittent allergic rhinitis (presence of symptoms less than 4 days per week or less than 4 weeks) should be carried out taking into account the anamnesis: stop after the symptoms disappear and resume after their reappearance.

In case of persistent allergic rhinitis (presence of symptoms more than 4 days a week or more than 4 weeks), treatment should be continued throughout the entire period of contact with the allergen.

Features

Pregnant women

Desloratadine has not been shown to be teratogenic in animal studies. The safety of the drug during pregnancy has not been established, therefore the use of desloratadine during this period is not recommended.

Desloratadine passes into breast milk, so its use in breastfeeding women is not recommended.

Children

Most cases of rhinitis in children under 2 years of age are infectious and there are no data to support the treatment of infectious rhinitis with desloratadine.

Drivers

According to clinical studies, desloratadine has no or very little effect on the ability to drive and use machines.

Overdose

In case of overdose, adverse reactions are similar to those observed at therapeutic doses, but the manifestations may be more severe.

In case of overdose, standard measures are used to remove unabsorbed active substance, and symptomatic treatment is used.

When desloratadine was used in doses up to 45 mg (9 times the recommended dose) in clinical studies in adults and adolescents, no clinically significant effects were observed.

Desloratadine is not removed by hemodialysis, and its removal by peritoneal dialysis has not been established.

Side effects

In clinical trials for indications including allergic rhinitis and chronic idiopathic urticaria, adverse reactions to desloratadine were reported at a rate of 3% more frequently in patients receiving the recommended dose of 5 mg daily than in patients receiving placebo.

The most frequently reported adverse reactions compared to placebo were fatigue (1.2%), dry mouth (0.8%), and headache (0.6%).

Interaction

Clinically significant changes in the concentration of desloratadine in the blood plasma with repeated use with ketoconazole, erythromycin, azithromycin, fluoxetine, cytimedine were not established. Due to the fact that the enzyme responsible for the metabolism of desloratadine has not been identified, interactions with other drugs cannot be completely excluded.

Storage conditions

Keep out of reach of children.

Store in the original package to protect from light.

This medicine does not require special temperature storage conditions.

Shelf life: 2 years.

The shelf life after opening the bottle is 3 months.